Canada: Life Sciences Team Advises Crescendo Biologics On $790 Million Collaboration With Takeda Pharmaceutical Company
Last Updated: September 11 2017

Crescendo Biologics turned to Gowling WLG's Life Sciences team, led by partner Patrick Duxbury, for assistance on its collaboration with Takeda Pharmaceutical Company with the aim of discovering, developing and commercialising Humabody®-based therapeutics aimed at cancer indications with a high unmet medical need.

Crescendo will use its patented transgenic platform and protein engineering expertise to develop Humabody® candidates against targets nominated by Takeda.

Under the term of the collaboration, Crescendo is entitled to receive up to $36 million via a series of milestones, funding, investment and upfront payment, while Takeda has the right to develop and commercialise selected Humabody®-based therapeutics arising from the partnership, triggering further payments of up $754 million.

The deal completed in October 2016.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Jason Coates, Ian Chapman-Curry
By Jason Coates, Ian Chapman-Curry
By Justin Smith, Kristen Kilroy, John Norman
By Alex Zavaglia
By Clark Sargent, Teresa Edwards
By Jason Coates, Christopher Stiles
By Andrew Smith, Philip Baker, Teresa Edwards
By Anurag (Ragi) Singh
By Ruth Ormston, Richard Lee
By Ian Weatherall, Turon Miah, Jane Bates
Tools
Print
Font Size:
Translation
Channels